BibTex RIS Kaynak Göster

Acute myeloid leukemia under lenalidomide therapy in a patient with multiple myeloma

Yıl 2016, Cilt: 3 Sayı: 3, 151 - 2, 15.03.2016

Ali Eser Funda Pepedil Tanrikulu , Ayse Tulin Firatli Tuglular

https://izlik.org/JA82YR69UY

Öz

A 53-year-old patient who had a 7 year history of multiple myeloma was diagnosed with high risk myelodysplastic syndrome while on lenalidomide treatment. Progression to acute myeloid leukemia has occurred during the following 4 months. Like our case, secondary primary malignancies (SPMs) can rarely complicate treatment of multiple myeloma. Although possible association between SPMs in patients receiving lenalidomide can be attributed to previous melphalan use, potential SPM risk with lenalidomide cannot still be ruled out safely

 

Anahtar Kelimeler

Multiple myeloma; Lenalidomide; Acute myeloid leukemia

Kaynakça

  • Kyle RA, Pierre RV, Bayrd ED. Multiple myeloma and acute myelomonocytic leukemia. N Engl J Med. 1970;283(21):1121-5.
  • Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782-91.
  • McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770-81.
  • Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759-69.
  • Dimopoulos MA, Richardson PG, Brandenburg N, Yu Z, Weber DM, Niesvizky R, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood. 2012;119(12):2764-7.
  • Rossi AC, Mark TM, Jayabalan D, Christos PJ, Zafar F, Pekle K, et al. Incidence of second primary malignancies (SPM) after 6-years follow-up of continuous lenalidomide in first-line treatment of multiple myeloma (MM). J Clin Oncol. 2011;29: abstr 8008.

Acute myeloid leukemia under lenalidomide therapy in a patient with multiple myeloma

Yıl 2016, Cilt: 3 Sayı: 3, 151 - 2, 15.03.2016

Ali Eser Funda Pepedil Tanrikulu , Ayse Tulin Firatli Tuglular

https://izlik.org/JA82YR69UY

Öz

Kaynakça

  • Kyle RA, Pierre RV, Bayrd ED. Multiple myeloma and acute myelomonocytic leukemia. N Engl J Med. 1970;283(21):1121-5.
  • Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782-91.
  • McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770-81.
  • Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759-69.
  • Dimopoulos MA, Richardson PG, Brandenburg N, Yu Z, Weber DM, Niesvizky R, et al. A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood. 2012;119(12):2764-7.
  • Rossi AC, Mark TM, Jayabalan D, Christos PJ, Zafar F, Pekle K, et al. Incidence of second primary malignancies (SPM) after 6-years follow-up of continuous lenalidomide in first-line treatment of multiple myeloma (MM). J Clin Oncol. 2011;29: abstr 8008.
Toplam 6 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Yazarlar

Ali Eser Bu kişi benim

Funda Pepedil Tanrikulu

Ayse Tulin Firatli Tuglular Bu kişi benim

Yayımlanma Tarihi 15 Mart 2016
DOI https://doi.org/10.17546/msd.84603
IZ https://izlik.org/JA82YR69UY
Yayımlandığı Sayı Yıl 2016 Cilt: 3 Sayı: 3

Kaynak Göster

APA Eser, A., Pepedil Tanrikulu, F., & Firatli Tuglular, A. T. (2016). Acute myeloid leukemia under lenalidomide therapy in a patient with multiple myeloma. Medical Science and Discovery, 3(3), 151-2. https://doi.org/10.17546/msd.84603
AMA 1.Eser A, Pepedil Tanrikulu F, Firatli Tuglular AT. Acute myeloid leukemia under lenalidomide therapy in a patient with multiple myeloma. Med Sci Discov. 2016;3(3):151-2. doi:10.17546/msd.84603
Chicago Eser, Ali, Funda Pepedil Tanrikulu, ve Ayse Tulin Firatli Tuglular. 2016. “Acute myeloid leukemia under lenalidomide therapy in a patient with multiple myeloma”. Medical Science and Discovery 3 (3): 151-2. https://doi.org/10.17546/msd.84603.
EndNote Eser A, Pepedil Tanrikulu F, Firatli Tuglular AT (01 Mart 2016) Acute myeloid leukemia under lenalidomide therapy in a patient with multiple myeloma. Medical Science and Discovery 3 3 151–2.
IEEE [1]A. Eser, F. Pepedil Tanrikulu, ve A. T. Firatli Tuglular, “Acute myeloid leukemia under lenalidomide therapy in a patient with multiple myeloma”, Med Sci Discov, c. 3, sy 3, ss. 151–2, Mar. 2016, doi: 10.17546/msd.84603.
ISNAD Eser, Ali - Pepedil Tanrikulu, Funda - Firatli Tuglular, Ayse Tulin. “Acute myeloid leukemia under lenalidomide therapy in a patient with multiple myeloma”. Medical Science and Discovery 3/3 (01 Mart 2016): 151-2. https://doi.org/10.17546/msd.84603.
JAMA 1.Eser A, Pepedil Tanrikulu F, Firatli Tuglular AT. Acute myeloid leukemia under lenalidomide therapy in a patient with multiple myeloma. Med Sci Discov. 2016;3:151–2.
MLA Eser, Ali, vd. “Acute myeloid leukemia under lenalidomide therapy in a patient with multiple myeloma”. Medical Science and Discovery, c. 3, sy 3, Mart 2016, ss. 151-2, doi:10.17546/msd.84603.
Vancouver 1.Eser A, Pepedil Tanrikulu F, Firatli Tuglular AT. Acute myeloid leukemia under lenalidomide therapy in a patient with multiple myeloma. Med Sci Discov [Internet]. 01 Mart 2016;3(3):151-2. Erişim adresi: https://izlik.org/JA82YR69UY